Mangoceuticals Seeks 1-for-2 to 1-for-25 Reverse Split to Hold Nasdaq Listing
MGRX sits 17% above its 52-week low of $0.162 on light trading volume (0.2× avg).
Summary
Mangoceuticals' proxy asks shareholders to authorize a reverse split of 1-for-2 up to 1-for-25 to cure a Nasdaq bid-price deficiency, and to expand the 2022 equity plan to 15,000,000 shares, resetting to 10,000,000 after any split.
Key Events · Corporate Governance and Compliance · MGRX
-
Reverse Split Authority Sought
Proposal 2 would let the board effect a reverse split at any ratio from 1-for-2 to 1-for-25, with the exact ratio set by the board, at any time before December 30, 2027.
-
Nasdaq Bid-Price Deadline Looms
Nasdaq notified the company on February 4, 2026 that it was below the $1.00 minimum bid; a second compliance period runs to February 1, 2027, after which delisting follows absent a cure.
-
Prior Split Limits Remedies
A 1-for-15 reverse split was effective October 16, 2024; under Nasdaq Rule 5810(c)(3)(A)(iv), falling below $1.00 again within one year, or reaching a 250-to-1 cumulative ratio in two years, brings a delisting determination instead of a new compliance period.
-
Equity Plan Reserve Expanded
The Third Amendment raises the 2022 Plan reserve to 15,000,000 shares from 11,588,880, then resets it to 10,000,000 shares immediately after any reverse split regardless of ratio, with a 26,000,000-share aggregate cap.
Analysis · MGRX · Industrial Applications And Services
Survival on Nasdaq, not cosmetics, is why Mangoceuticals is asking shareholders to hand the board authority for a reverse split of up to 1-for-25. The stock has traded below the $1.00 minimum bid since a February 4, 2026 notice, and the second compliance window closes February 1, 2027. A prior 1-for-15 split took effect October 16, 2024, which matters because Nasdaq rules strip the compliance period from any company that falls back under $1.00 within a year of a split, or that accumulates a 250-to-1 ratio over two years — so a second failure would trigger a delisting determination rather than another grace period. Bundled with the split is a bigger equity plan: the reserve rises to 15,000,000 shares and resets to 10,000,000 post-split regardless of ratio, which the proxy itself says may cause substantial dilution. Against a $229K cash balance and a going-concern warning in the last 10-Q, the reverse split is the mechanism that keeps the equity currency usable.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.19 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.16 to $2.41. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.